Market research
HO1.F Hologic, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 15B
- P/E ratio
- 31.1
- Analyst target
- 85.5
- Dividend yield
- Not available
- Beta
- 0.7
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- US4364401012
- Market cap
- 15B
- P/E ratio
- 31.1
- Analyst target
- 85.5
- Dividend yield
- Not available
- Beta
- 0.7
About
About Hologic, Inc
Hologic, Inc. engages in the development, manufacture, and supply of diagnostic products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analysis software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology systems; and breast conserving surgery products. In addition, the company provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system. It offers women's health products, including breast health, gynecological health, sexual health, body composition, and skeletal health. The company sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is based in Marlborough, Massachusetts. As of April 7, 2
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HO1.F discussion.
5 years, 5 months ago
Hologic, Inc is currently in a long term downtrend where the price is trading 1.3% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.3.
Hologic, Inc's total revenue rose by 89.3% to $2B since the same quarter in the previous year.
Its net income has increased by 69.5% to $654M since the same quarter in the previous year.
Finally, its free cash flow grew by 634.5% to $605M since the same quarter in the previous year.
Based on the above factors, Hologic, Inc gets an overall score of 4/5.